<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on September 8, 2026 at 4:56 AM by All in One SEO v5.0.1.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://cgxpwire.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>cGxP.wire</title>
		<link><![CDATA[https://cgxpwire.com]]></link>
		<description><![CDATA[cGxP.wire]]></description>
		<lastBuildDate><![CDATA[Tue, 08 Sep 2026 05:55:55 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://cgxpwire.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://cgxpwire.com/prodia-the-cro-receives-frost-sullivan-2026-customer-value-recognition/]]></guid>
			<link><![CDATA[https://cgxpwire.com/prodia-the-cro-receives-frost-sullivan-2026-customer-value-recognition/]]></link>
			<title>Prodia the CRO Receives Frost &amp; Sullivan 2026 Customer Value Recognition</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 05:55:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/delveinsight-cabp-market-set-for-growth-through-2036/]]></guid>
			<link><![CDATA[https://cgxpwire.com/delveinsight-cabp-market-set-for-growth-through-2036/]]></link>
			<title>DelveInsight: CABP Market Set for Growth Through 2036</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 05:36:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/nyxoah-begins-u-s-breathe-study-with-first-genio-implant/]]></guid>
			<link><![CDATA[https://cgxpwire.com/nyxoah-begins-u-s-breathe-study-with-first-genio-implant/]]></link>
			<title>Nyxoah Begins U.S. BREATHE Study With First Genio Implant</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 05:34:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/aptar-pharma-aceso-advance-inhaled-aso-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/aptar-pharma-aceso-advance-inhaled-aso-therapy/]]></link>
			<title>Aptar Pharma, Aceso Advance Inhaled ASO Therapy</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 05:31:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/guardant-health-wins-fda-approval-for-breast-cancer-cdx/]]></guid>
			<link><![CDATA[https://cgxpwire.com/guardant-health-wins-fda-approval-for-breast-cancer-cdx/]]></link>
			<title>Guardant Health Wins FDA Approval for Breast Cancer CDx</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 05:24:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/novo-nordisk-reports-positive-step-young-phase-3-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/novo-nordisk-reports-positive-step-young-phase-3-data/]]></link>
			<title>Novo Nordisk Reports Positive STEP Young Phase 3 Data</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 05:22:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/resonant-expands-biorepository-network-with-creapharm-deal/]]></guid>
			<link><![CDATA[https://cgxpwire.com/resonant-expands-biorepository-network-with-creapharm-deal/]]></link>
			<title>Resonant Expands Biorepository Network With Creapharm Deal</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 05:18:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cellupro-gains-excipact-gmp-certification-in-china/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cellupro-gains-excipact-gmp-certification-in-china/]]></link>
			<title>CelluPro Gains EXCiPACT GMP Certification in China</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 05:17:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/fda-acts-to-protect-access-to-newborn-nutrition-products/]]></guid>
			<link><![CDATA[https://cgxpwire.com/fda-acts-to-protect-access-to-newborn-nutrition-products/]]></link>
			<title>FDA Acts to Protect Access to Newborn Nutrition Products</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 05:04:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/vertex-completes-crinetics-acquisition-in-10-billion-deal/]]></guid>
			<link><![CDATA[https://cgxpwire.com/vertex-completes-crinetics-acquisition-in-10-billion-deal/]]></link>
			<title>Vertex Completes Crinetics Acquisition in $10 Billion Deal</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 04:58:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/fosun-pharma-launches-hk1-billion-h-share-repurchase/]]></guid>
			<link><![CDATA[https://cgxpwire.com/fosun-pharma-launches-hk1-billion-h-share-repurchase/]]></link>
			<title>Fosun Pharma Launches HK$1 Billion H-Share Repurchase</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 04:54:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/fda-grants-accelerated-approval-to-etcamah-for-breast-cancer/]]></guid>
			<link><![CDATA[https://cgxpwire.com/fda-grants-accelerated-approval-to-etcamah-for-breast-cancer/]]></link>
			<title>FDA Grants Accelerated Approval to Etcamah for Breast Cancer</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 04:53:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/synact-pharma-advances-resomelagon-toward-phase-3-in-ra/]]></guid>
			<link><![CDATA[https://cgxpwire.com/synact-pharma-advances-resomelagon-toward-phase-3-in-ra/]]></link>
			<title>SynAct Pharma Advances Resomelagon Toward Phase 3 in RA</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 04:46:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/ascletis-joins-hong-kong-stock-connect-programs/]]></guid>
			<link><![CDATA[https://cgxpwire.com/ascletis-joins-hong-kong-stock-connect-programs/]]></link>
			<title>Ascletis Joins Hong Kong Stock Connect Programs</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 04:37:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/matricelf-gains-fda-feedback-for-newral-spinal-injury-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/matricelf-gains-fda-feedback-for-newral-spinal-injury-trial/]]></link>
			<title>Matricelf Gains FDA Feedback for NewRal Spinal Injury Trial</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 04:32:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/mabwell-reports-9mw1911-copd-phase-ib-iia-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/mabwell-reports-9mw1911-copd-phase-ib-iia-results/]]></link>
			<title>Mabwell Reports 9MW1911 COPD Phase Ib/IIa Results</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 04:24:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/insilico-rentosertib-shows-potential-for-biological-age-reversal/]]></guid>
			<link><![CDATA[https://cgxpwire.com/insilico-rentosertib-shows-potential-for-biological-age-reversal/]]></link>
			<title>Insilico Rentosertib Shows Potential for Biological Age Reversal</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 04:21:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/rznomics-advances-high-efficiency-circular-rna-production/]]></guid>
			<link><![CDATA[https://cgxpwire.com/rznomics-advances-high-efficiency-circular-rna-production/]]></link>
			<title>RZNOMICS Advances High-Efficiency Circular RNA Production</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 04:20:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/teva-reaches-investment-grade-with-sp-bbb-upgrade/]]></guid>
			<link><![CDATA[https://cgxpwire.com/teva-reaches-investment-grade-with-sp-bbb-upgrade/]]></link>
			<title>Teva Reaches Investment Grade With S&amp;P BBB- Upgrade</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 04:09:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/tyra-to-present-dabogratinib-phase-2-bladder-cancer-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/tyra-to-present-dabogratinib-phase-2-bladder-cancer-data/]]></link>
			<title>Tyra to Present Dabogratinib Phase 2 Bladder Cancer Data</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 04:06:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/inhibrx-to-present-inbrx-106-phase-2-hnscc-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/inhibrx-to-present-inbrx-106-phase-2-hnscc-results/]]></link>
			<title>Inhibrx to Present INBRX-106 Phase 2 HNSCC Results</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 03:48:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/lupin-wins-fda-approval-for-modafinil-tablets-in-u-s/]]></guid>
			<link><![CDATA[https://cgxpwire.com/lupin-wins-fda-approval-for-modafinil-tablets-in-u-s/]]></link>
			<title>Lupin Wins FDA Approval for Modafinil Tablets in U.S.</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 03:43:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/samsung-bioepis-gains-japan-approval-for-ustekinumab-biosimilar/]]></guid>
			<link><![CDATA[https://cgxpwire.com/samsung-bioepis-gains-japan-approval-for-ustekinumab-biosimilar/]]></link>
			<title>Samsung Bioepis Gains Japan Approval for Ustekinumab Biosimilar</title>
			<pubDate><![CDATA[Tue, 08 Sep 2026 03:39:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/roivant-and-pulmovant-to-unveil-topline-mosliciguat-results-in-ph-ild/]]></guid>
			<link><![CDATA[https://cgxpwire.com/roivant-and-pulmovant-to-unveil-topline-mosliciguat-results-in-ph-ild/]]></link>
			<title>Roivant and Pulmovant to Unveil Topline Mosliciguat Results in PH-ILD</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 07:26:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/astrazeneca-wins-u-s-approval-for-etcamah-in-breast-cancer/]]></guid>
			<link><![CDATA[https://cgxpwire.com/astrazeneca-wins-u-s-approval-for-etcamah-in-breast-cancer/]]></link>
			<title>AstraZeneca Wins U.S. Approval for ETCAMAH in Breast Cancer</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 06:05:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/novartis-and-ionis-pharmaceuticals-face-setback-in-pelacarsen-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/novartis-and-ionis-pharmaceuticals-face-setback-in-pelacarsen-trial/]]></link>
			<title>Novartis and Ionis Pharmaceuticals Face Setback in Pelacarsen Trial</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 05:57:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/modular-medical-expands-pivot-pump-access-through-u-s-pbm-contract/]]></guid>
			<link><![CDATA[https://cgxpwire.com/modular-medical-expands-pivot-pump-access-through-u-s-pbm-contract/]]></link>
			<title>Modular Medical Expands Pivot Pump Access Through U.S. PBM Contract</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 05:32:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biogen-reports-long-term-zorevunersen-data-in-dravet-syndrome/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biogen-reports-long-term-zorevunersen-data-in-dravet-syndrome/]]></link>
			<title>Biogen Reports Long-Term Zorevunersen Data in Dravet Syndrome</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 05:27:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/argo-biopharma-reports-positive-phase-ii-data-for-bw-20805-in-hae/]]></guid>
			<link><![CDATA[https://cgxpwire.com/argo-biopharma-reports-positive-phase-ii-data-for-bw-20805-in-hae/]]></link>
			<title>Argo Biopharma Reports Positive Phase II Data for BW-20805 in HAE</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 05:23:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/fda-seeks-input-to-advance-botanical-drug-development/]]></guid>
			<link><![CDATA[https://cgxpwire.com/fda-seeks-input-to-advance-botanical-drug-development/]]></link>
			<title>FDA Seeks Input to Advance Botanical Drug Development</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 05:20:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/fda-seeks-input-to-advance-botanical-drug-development/]]></guid>
			<link><![CDATA[https://cgxpwire.com/fda-seeks-input-to-advance-botanical-drug-development/]]></link>
			<title>FDA Seeks Input to Advance Botanical Drug Development</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 05:20:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/evinova-and-lothar-medical-partner-to-modernize-respiratory-trials/]]></guid>
			<link><![CDATA[https://cgxpwire.com/evinova-and-lothar-medical-partner-to-modernize-respiratory-trials/]]></link>
			<title>Evinova and Lothar Medical Partner to Modernize Respiratory Trials</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 05:19:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/abbvie-completes-10-9-billion-apogee-acquisition/]]></guid>
			<link><![CDATA[https://cgxpwire.com/abbvie-completes-10-9-billion-apogee-acquisition/]]></link>
			<title>AbbVie Completes $10.9 Billion Apogee Acquisition</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 05:16:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/acepodia-gains-fda-ind-clearance-for-ace723-adc/]]></guid>
			<link><![CDATA[https://cgxpwire.com/acepodia-gains-fda-ind-clearance-for-ace723-adc/]]></link>
			<title>Acepodia Gains FDA IND Clearance for ACE723 ADC</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 05:13:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/agilent-launches-s540md-slide-scanner-in-the-u-s/]]></guid>
			<link><![CDATA[https://cgxpwire.com/agilent-launches-s540md-slide-scanner-in-the-u-s/]]></link>
			<title>Agilent Launches S540MD Slide Scanner in the U.S.</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 05:08:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/rezubio-advances-rz-520-with-fda-and-nmpa-ind-clearances/]]></guid>
			<link><![CDATA[https://cgxpwire.com/rezubio-advances-rz-520-with-fda-and-nmpa-ind-clearances/]]></link>
			<title>Rezubio Advances RZ-520 with FDA and NMPA IND Clearances</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:59:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cytek-biosciences-highlights-spectral-flow-cytometry-at-escca/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cytek-biosciences-highlights-spectral-flow-cytometry-at-escca/]]></link>
			<title>Cytek Biosciences Highlights Spectral Flow Cytometry at ESCCA</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:51:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/globus-medical-gains-ce-mark-for-excelsius3d-imaging/]]></guid>
			<link><![CDATA[https://cgxpwire.com/globus-medical-gains-ce-mark-for-excelsius3d-imaging/]]></link>
			<title>Globus Medical Gains CE Mark for Excelsius3D Imaging</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:50:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/persica-strengthens-pp353-case-in-vertebrogenic-back-pain/]]></guid>
			<link><![CDATA[https://cgxpwire.com/persica-strengthens-pp353-case-in-vertebrogenic-back-pain/]]></link>
			<title>Persica Strengthens PP353 Case in Vertebrogenic Back Pain</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:45:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/abbvie-reports-positive-phase-3-etentamig-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/abbvie-reports-positive-phase-3-etentamig-results/]]></link>
			<title>AbbVie Reports Positive Phase 3 Etentamig Results</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:43:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clearmind-advances-cmnd-100-into-phase-iia-trial-for-alcohol-use-disorder/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clearmind-advances-cmnd-100-into-phase-iia-trial-for-alcohol-use-disorder/]]></link>
			<title>Clearmind Advances CMND-100 Into Phase IIa Trial for Alcohol Use Disorder</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:41:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/fda-authorizes-nitenpyram-for-new-world-screwworm/]]></guid>
			<link><![CDATA[https://cgxpwire.com/fda-authorizes-nitenpyram-for-new-world-screwworm/]]></link>
			<title>FDA Authorizes Nitenpyram for New World Screwworm</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:38:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/alcon-launches-unity-m-ophthalmic-microscope-for-enhanced-surgical-precision/]]></guid>
			<link><![CDATA[https://cgxpwire.com/alcon-launches-unity-m-ophthalmic-microscope-for-enhanced-surgical-precision/]]></link>
			<title>Alcon Launches UNITY M Ophthalmic Microscope for Enhanced Surgical Precision</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:38:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/gsk-files-eu-submission-for-lower-carbon-ventolin/]]></guid>
			<link><![CDATA[https://cgxpwire.com/gsk-files-eu-submission-for-lower-carbon-ventolin/]]></link>
			<title>GSK Files EU Submission for Lower-Carbon Ventolin</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:35:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/iqvia-launches-ai-powered-predictive-clinical-development/]]></guid>
			<link><![CDATA[https://cgxpwire.com/iqvia-launches-ai-powered-predictive-clinical-development/]]></link>
			<title>IQVIA Launches AI-Powered Predictive Clinical Development</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:33:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/fda-approves-zanvastro-as-first-alexander-disease-drug/]]></guid>
			<link><![CDATA[https://cgxpwire.com/fda-approves-zanvastro-as-first-alexander-disease-drug/]]></link>
			<title>FDA Approves Zanvastro as First Alexander Disease Drug</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:32:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/egenesis-reports-kidney-xenotransplantation-clinical-progress/]]></guid>
			<link><![CDATA[https://cgxpwire.com/egenesis-reports-kidney-xenotransplantation-clinical-progress/]]></link>
			<title>eGenesis Reports Kidney Xenotransplantation Clinical Progress</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:29:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/cipla-partners-with-qilu-on-keytruda-biosimilar/]]></guid>
			<link><![CDATA[https://cgxpwire.com/cipla-partners-with-qilu-on-keytruda-biosimilar/]]></link>
			<title>Cipla Partners with Qilu on Keytruda Biosimilar</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:28:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/curia-expands-albuquerque-facility-for-sterile-drug-manufacturing/]]></guid>
			<link><![CDATA[https://cgxpwire.com/curia-expands-albuquerque-facility-for-sterile-drug-manufacturing/]]></link>
			<title>Curia Expands Albuquerque Facility for Sterile Drug Manufacturing</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:23:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/philips-launches-ev14-2v-transducer-for-womens-health/]]></guid>
			<link><![CDATA[https://cgxpwire.com/philips-launches-ev14-2v-transducer-for-womens-health/]]></link>
			<title>Philips Launches eV14-2v Transducer for Women’s Health</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 04:19:10 +0000]]></pubDate>
		</item>
				</channel>
</rss>
